Hexagon Capital Partners LLC Grows Holdings in Pfizer Inc. (NYSE:PFE)

Hexagon Capital Partners LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 41,162 shares of the biopharmaceutical company’s stock after purchasing an additional 3,101 shares during the period. Pfizer makes up approximately 0.3% of Hexagon Capital Partners LLC’s investment portfolio, making the stock its 27th largest position. Hexagon Capital Partners LLC’s holdings in Pfizer were worth $1,185,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the period. Morgan Stanley boosted its stake in shares of Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares during the period. Invesco Ltd. boosted its stake in shares of Pfizer by 30.9% in the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock valued at $797,901,000 after purchasing an additional 5,678,004 shares during the period. Finally, California Public Employees Retirement System boosted its stake in shares of Pfizer by 0.6% in the third quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock valued at $609,692,000 after purchasing an additional 101,256 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on PFE. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.03 on Tuesday, reaching $25.61. 37,889,007 shares of the company were exchanged, compared to its average volume of 41,962,758. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The firm has a market cap of $145.02 billion, a price-to-earnings ratio of 71.14, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The company has a 50-day moving average of $26.88 and a 200-day moving average of $28.26.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the firm earned $1.14 EPS. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.56%. Pfizer’s dividend payout ratio is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.